To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Dextrorphan (DXO) is a pharmacologically active metabolite of dextromethorphan (DXM).
Dextrorphan is structurally similar to dextromethorphan, and has an affinity for the same receptors in the central nervous system, although with a slight difference in selectivity. While dextromethorphan is a weak non-competitive NMDA receptor antagonist, dextrorphan is a more potent antagonist.
It should be noted, however, that due to its potency as an NMDA receptor antagonist, as well as the fact that it is produced as a by-product of DXM metabolization in the body, DXO is thought to be largely responsible for the psychological side-effects that occur at high doses of DXM. These side-effects can include alteration of consciousness, or "cognitive dissociation", which are characteristic of NMDA blockade and which have afforded DXM its potential for use as a recreational drug.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dextrorphan". A list of authors is available in Wikipedia.|